MK-677 and Muscle Mass in the Elderly: The Evidence

MK-677

1.1 kg gain

MK-677 increased fat-free mass by 1.1 kg over 12 months in healthy adults aged 60-81, while the placebo group lost 0.5 kg. Strength did not change.

Nass et al., Annals of Internal Medicine, 2008

Nass et al., Annals of Internal Medicine, 2008

View as image

Sarcopenia, the age-related loss of muscle mass and function, affects an estimated 10-16% of adults over 60 worldwide. Growth hormone and IGF-1 decline steadily with aging, a process called somatopause, and this decline correlates with the progressive loss of lean tissue. MK-677 (ibutamoren), the oral growth hormone secretagogue covered in depth in our pillar article, has been studied specifically for its ability to reverse this trajectory. The central question is straightforward: does restoring youthful GH and IGF-1 levels translate into meaningful muscle preservation or recovery in older adults? The data provides a clear answer on body composition and a frustrating one on function.

The Nass 2008 trial: 2 years of evidence

The Nass study is the most important trial for evaluating MK-677's effects on muscle mass in aging.^[1] Sixty-five healthy adults aged 60-81 were randomized to MK-677 25 mg or placebo daily in a modified crossover design. Three cohorts were studied: 23 men, 25 women on hormone replacement therapy, and 17 women not on HRT. Body composition was measured by dual-energy X-ray absorptiometry (DEXA).

Over 12 months, fat-free mass increased 1.1 kg in the MK-677 group while decreasing 0.5 kg in the placebo group (P < 0.001). This 1.6 kg advantage represents a meaningful body composition shift. Total body fat did not change significantly, meaning the MK-677 group gained lean tissue without proportional fat loss.

But the critical finding: none of this translated into improved strength or function. Grip strength, stair climb power, tandem walk, and chair rise time showed no significant differences between groups at any time point during the 2-year study.^[1]

This dissociation between mass and function is the defining result of the MK-677 sarcopenia literature. Adding tissue that does not produce proportional force challenges the premise that restoring GH-mediated anabolism is sufficient to combat functional decline in aging.

Why mass increased without strength

Several explanations for this mass-function disconnect have been proposed.

Water retention inflates DEXA measurements. GH promotes sodium and water retention. DEXA measures fat-free mass, which includes intracellular water, extracellular fluid, and muscle protein. An increase in total body water would register as increased fat-free mass without corresponding contractile protein gains. The Nass trial reported transient lower-extremity edema in the MK-677 group, suggesting fluid shifts contributed to at least some of the measured mass increase.^[1]

Connective tissue may expand without muscle fiber hypertrophy. GH and IGF-1 stimulate collagen synthesis in tendons, fascia, and the extracellular matrix of muscle. This increases tissue volume (measured as fat-free mass) without necessarily adding sarcomeric protein, the contractile machinery that generates force.

The anabolic signal may be insufficient for functional recovery. Sarcopenia involves not just muscle atrophy but also motor unit loss, neuromuscular junction deterioration, increased intermuscular fat infiltration, and changes in muscle fiber type composition. GH and IGF-1 address the protein synthesis side of the equation but do not repair denervated motor units or reverse fiber type shifts from Type II (fast-twitch) to Type I (slow-twitch). Functional recovery may require the combination of anabolic stimulus plus mechanical loading (exercise).

The study was underpowered for functional endpoints. The authors acknowledged this limitation: 65 participants over 2 years provided insufficient statistical power to detect changes in functional measures. Functional decline in healthy elderly adults occurs slowly, and the variance in functional tests is large. A larger trial might have detected smaller but real functional improvements that this study missed.

Earlier MK-677 data: what Chapman established

Chapman's 1996 study provided the first evidence that MK-677 could restore the GH-IGF-1 axis in elderly adults.^[2] Thirty-two healthy subjects aged 64-81 received MK-677 at 2, 10, or 25 mg daily or placebo for 14 and 28-day periods.

At 25 mg/day, mean 24-hour GH concentration increased 97% from baseline. Serum IGF-1 rose from 141 micrograms/L at baseline to 219 at 2 weeks and 265 at 4 weeks, reaching the normal range for healthy young adults. The increase came from enhanced pulsatile GH secretion: pulse height and nadir levels both increased without changing the number of pulses per day.^[2]

The 4-week duration was too short to measure muscle mass changes, but the study proved MK-677 could correct the somatopause at the hormonal level. The question of whether correcting the hormonal deficit translates into tissue-level and functional benefits is what the later studies tried to answer.

Hip fracture trials: when muscle recovery is urgent

Two trials tested MK-677 in elderly patients recovering from hip fracture, a population where muscle wasting is acute, severe, and directly linked to mortality.

Bach and colleagues (2004) randomized hip fracture patients to MK-677 25 mg or placebo during the acute recovery period.^[3] IGF-1 levels rose as expected. The trial was relatively small and short, limiting conclusions about functional recovery.

The larger Adunsky 2011 trial randomized 123 elderly hip fracture patients (mean age approximately 80) to MK-677 25 mg or placebo for 24 weeks.^[4] Gait speed improved by a 0.7-point difference in the MK-677 group versus placebo (P = 0.011), and IGF-1 increased by 51.4 ng/mL compared to placebo. This was the only MK-677 trial to show a functional benefit, and the magnitude was small.

The trial was stopped early because 4 MK-677 patients (6.5%) developed congestive heart failure versus 1 on placebo (1.7%). The frail, elderly, post-surgical population was particularly vulnerable to GH-induced fluid retention. The GH secretagogue risk profile article covers this safety signal in detail.

Capromorelin: the same pattern with a different secretagogue

MK-677 is not the only secretagogue tested for body composition in aging. White and colleagues studied capromorelin, another oral GH secretagogue, in 395 adults aged 65-84 randomized to multiple dosing regimens or placebo for 12 months.^[5]

Lean body mass increased by approximately 1.4 kg with capromorelin versus placebo. But, as with MK-677, functional measures did not improve. The study was terminated early based on predetermined criteria, and adverse events included increases in fasting glucose, HbA1c, and insulin resistance.

The consistency of this pattern across two different secretagogues and independent research groups strengthens the conclusion: oral GH secretagogues increase measured lean mass in elderly adults but do not produce detectable functional improvements in the trial designs used so far.

What Svensson showed in younger obese men

Svensson's 1998 study tested MK-677 25 mg daily in 24 obese men (mean BMI approximately 33) for 8 weeks.^[6] Serum IGF-1 increased approximately 40%, and fat-free mass rose significantly. Fat mass did not change, meaning any body composition benefit came from adding lean tissue rather than losing fat.

This study in a younger population confirmed MK-677's anabolic signal is not limited to the elderly. But it also showed the metabolic cost: oral glucose tolerance deteriorated at both 2 and 8 weeks, even though fasting glucose remained normal. The implication is that standard fasting blood work would miss the glucose metabolism impairment.

Sermorelin: a different approach to the same problem

Khorram and colleagues took a different approach, using a GHRH analog (related to sermorelin) in age-advanced adults for 16 weeks.^[7] The compound increased GH and IGF-1 levels, improved lean body mass, and did not produce the insulin resistance seen with MK-677. This distinction is important: GHRH analogs stimulate GH release through a different receptor than ghrelin mimetics, and their metabolic profile may be cleaner.

Whether GHRH analogs produce functional benefits remains unstudied at sufficient scale. The 16-week duration was enough to show hormonal and body composition changes but too short for functional outcome assessment.

The 2023 state of the field

Smith and colleagues published a 2023 review in the Journals of Gerontology assessing whether GH secretagogues could serve as therapeutic agents for restoring GH secretion in older adults.^[8] The review concluded that oral GH secretagogues can reliably restore pulsatile GH secretion and IGF-1 levels to those observed in young adults. The GH peaks cannot be overstimulated because IGF-1 feedback regulates the maximum, providing a theoretical safety advantage over exogenous GH injection.

But the review also acknowledged the central problem: evidence that restoring youthful GH levels translates into clinically meaningful improvements in muscle function, physical performance, or quality of life in older adults remains insufficient. The gap between hormonal restoration and functional recovery has not been bridged.

The Sigalos 2018 review reached a similar conclusion from the safety side: GH secretagogues show promise for body composition but the long-term safety data gap and the absence of functional benefit evidence make their role in sarcopenia management uncertain.^[9]

The missing variable: exercise

The most conspicuous absence across all MK-677 sarcopenia trials is resistance exercise. No published trial has combined MK-677 with a structured exercise program and measured the combined effect on muscle mass and function.

This matters because the mechanistic argument for GH secretagogues in sarcopenia is strongest when combined with mechanical loading. GH and IGF-1 enhance protein synthesis, but protein synthesis must be directed toward contractile protein (myofibrillar) rather than non-contractile tissue. Resistance exercise provides the mechanical signal that directs protein synthesis toward sarcomeric protein. Without that signal, GH-stimulated anabolism may preferentially increase water content, connective tissue, and extracellular matrix rather than functional muscle fiber.

Exogenous GH combined with resistance exercise in elderly adults has shown additive effects in some studies and no additional benefit in others. Whether MK-677 plus exercise would outperform exercise alone is an unanswered question, and it is arguably the most clinically relevant one.

What we know and what we do not

The MK-677 sarcopenia evidence base supports three conclusions and leaves one critical question open.

Supported: MK-677 restores GH and IGF-1 to youthful levels in elderly adults. It increases DEXA-measured fat-free mass by approximately 1-1.5 kg over 12 months. These effects are reproducible across studies and consistent across different GH secretagogues.

Unsupported: MK-677 alone improves strength, physical function, or quality of life in elderly adults. The one positive functional finding (gait speed in hip fracture patients) was small and came from a trial stopped early for safety.

Uncertain: Whether the fat-free mass gains represent true muscle protein accretion or fluid and connective tissue expansion. Whether combining MK-677 with resistance exercise would unlock functional benefits. Whether the metabolic costs (insulin resistance, IGF-1 elevation risks) are justified by body composition changes that do not produce functional improvement.

The Bottom Line

MK-677 reliably increases fat-free mass by 1-1.5 kg in older adults over 12 months while restoring GH and IGF-1 to youthful levels. But across every controlled trial, this body composition improvement has not translated into measurable gains in strength, physical function, or quality of life. The disconnect likely reflects a combination of water retention inflating DEXA measurements, anabolic activity directed toward non-contractile tissue, and the absence of combined exercise interventions. Until a trial tests MK-677 plus resistance exercise against exercise alone, the compound's role in addressing sarcopenia remains theoretical.

Frequently Asked Questions

Does MK-677 build muscle in older adults?

MK-677 increases fat-free mass (lean body mass) by approximately 1.1 kg over 12 months in adults aged 60-81, as measured by DEXA scanning. However, this increase has not translated into improved grip strength, stair climbing ability, or any other functional measure in controlled trials. Some of the measured mass gain may reflect water retention rather than muscle protein.

Can MK-677 treat sarcopenia?

No controlled trial has demonstrated that MK-677 improves the functional deficits that define sarcopenia (muscle weakness and reduced physical performance). While it increases fat-free mass and restores IGF-1 to youthful levels, the 2008 Nass trial showed no improvement in strength or function over 2 years. MK-677 addresses the hormonal aspect of sarcopenia but has not been shown to reverse functional decline.

How much muscle does MK-677 add?

In the longest controlled trial, MK-677 at 25 mg daily for 12 months increased fat-free mass by 1.1 kg in healthy older adults, compared to a 0.5 kg decrease on placebo. Capromorelin, a similar secretagogue, increased lean mass by approximately 1.4 kg over 12 months. These gains are modest compared to the 2-4 kg that can be achieved with resistance exercise alone in elderly populations.

Does MK-677 help with hip fracture recovery?

In one trial of 123 elderly hip fracture patients, MK-677 improved gait speed modestly (0.7-point difference versus placebo) and increased IGF-1 by 51.4 ng/mL. However, the trial was stopped early because 6.5% of MK-677 patients developed congestive heart failure versus 1.7% on placebo, raising questions about safety in this vulnerable population.

Is MK-677 better than exercise for building muscle in the elderly?

No data suggests MK-677 is more effective than exercise for building functional muscle. Resistance exercise in elderly adults typically increases lean mass by 2-4 kg while also improving strength, balance, and physical function. MK-677 increases lean mass by approximately 1 kg without functional improvement. No trial has tested MK-677 combined with exercise versus exercise alone.

Why does MK-677 increase mass but not strength?

Several factors may explain this. GH promotes water and sodium retention, which inflates DEXA-measured fat-free mass without adding contractile muscle protein. GH also stimulates collagen synthesis in connective tissue, adding mass without force-generating capacity. Additionally, sarcopenia involves motor unit loss and nerve deterioration that GH cannot address. Resistance exercise may be needed to direct GH-stimulated protein synthesis toward functional muscle fibers.